These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 17054943

  • 1. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ.
    Eur J Pharmacol; 2006 Dec 28; 553(1-3):229-39. PubMed ID: 17054943
    [Abstract] [Full Text] [Related]

  • 2. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ.
    Eur J Pharmacol; 2007 Dec 22; 577(1-3):222-32. PubMed ID: 18074444
    [Abstract] [Full Text] [Related]

  • 3. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
    Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX.
    J Am Coll Cardiol; 1996 Dec 22; 28(7):1836-48. PubMed ID: 8962574
    [Abstract] [Full Text] [Related]

  • 4. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof P, Fabritz L, Breithardt G, Haverkamp W.
    J Pharmacol Exp Ther; 2002 Oct 22; 303(1):218-25. PubMed ID: 12235254
    [Abstract] [Full Text] [Related]

  • 5. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
    Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF.
    J Cardiovasc Pharmacol; 2001 May 22; 37(5):607-18. PubMed ID: 11336111
    [Abstract] [Full Text] [Related]

  • 6. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P, Hilker E, Ramtin S, Cakir Y, Stypmann J, Engelen MA, Mönnig G, Osada N, Breithardt G, Haverkamp W, Eckardt L.
    J Cardiovasc Electrophysiol; 2007 Jun 22; 18(6):647-54. PubMed ID: 17388913
    [Abstract] [Full Text] [Related]

  • 7. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit.
    Lu HR, Vlaminckx E, Teisman A, Gallacher DJ.
    J Pharmacol Toxicol Methods; 2005 Jun 22; 52(1):90-105. PubMed ID: 15978848
    [Abstract] [Full Text] [Related]

  • 8. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D, Penland RC, stamps A, Traebert M, Dumotier B, Georgiva A, Helmlinger G, Lett GS.
    Prog Biophys Mol Biol; 2006 Jun 22; 90(1-3):414-43. PubMed ID: 16321428
    [Abstract] [Full Text] [Related]

  • 9. Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide.
    Hanada E, Ohtani H, Hirota M, Uemura N, Nakaya H, Kotaki H, Sato H, Yamada Y, Iga T.
    J Pharm Pharmacol; 2003 Jul 22; 55(7):995-1002. PubMed ID: 12906757
    [Abstract] [Full Text] [Related]

  • 10. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N, Authier S, Pugsley MK, Curtis MJ.
    Toxicol Appl Pharmacol; 2010 Mar 01; 243(2):146-53. PubMed ID: 20005885
    [Abstract] [Full Text] [Related]

  • 11. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR, Yan GX, Gallacher DJ.
    J Pharmacol Toxicol Methods; 2013 Mar 01; 68(2):250-259. PubMed ID: 23337247
    [Abstract] [Full Text] [Related]

  • 12. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
    Aiba T, Shimizu W, Inagaki M, Noda T, Miyoshi S, Ding WG, Zankov DP, Toyoda F, Matsuura H, Horie M, Sunagawa K.
    J Am Coll Cardiol; 2005 Jan 18; 45(2):300-7. PubMed ID: 15653031
    [Abstract] [Full Text] [Related]

  • 13. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR, Gallacher DJ, Yan GX.
    J Pharmacol Toxicol Methods; 2016 Jan 18; 81():151-60. PubMed ID: 27374776
    [Abstract] [Full Text] [Related]

  • 14. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
    Ducroq J, Printemps R, Guilbot S, Gardette J, Salvetat C, Le Grand M.
    J Pharmacol Toxicol Methods; 2007 Jan 18; 56(2):159-70. PubMed ID: 17604185
    [Abstract] [Full Text] [Related]

  • 15. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
    Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R, Pugsley M, Gallacher DJ.
    Br J Pharmacol; 2008 Aug 18; 154(7):1427-38. PubMed ID: 18493243
    [Abstract] [Full Text] [Related]

  • 16. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM.
    J Cardiovasc Electrophysiol; 2006 Mar 18; 17(3):337-40. PubMed ID: 16643415
    [Abstract] [Full Text] [Related]

  • 17. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL, Pollard CE, Hammond TG, Valentin JP.
    J Pharmacol Toxicol Methods; 2005 Mar 18; 52(1):46-59. PubMed ID: 15975832
    [Abstract] [Full Text] [Related]

  • 18. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
    Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E, Engwall MJ, Zhou J.
    Br J Pharmacol; 2005 Nov 18; 146(6):792-9. PubMed ID: 16158069
    [Abstract] [Full Text] [Related]

  • 19. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
    Topilski I, Rogowski O, Rosso R, Justo D, Copperman Y, Glikson M, Belhassen B, Hochenberg M, Viskin S.
    J Am Coll Cardiol; 2007 Jan 23; 49(3):320-8. PubMed ID: 17239713
    [Abstract] [Full Text] [Related]

  • 20. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
    Briasoulis A, Agarwal V, Pierce WJ.
    Cardiology; 2011 Jan 23; 120(2):103-10. PubMed ID: 22156660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.